Navigation Links
Female Hormones Deter Salt-Sensitive Hypertension
Date:2/6/2009

Estrogen appears to improve kidneys' ability to shed sodium, study says

FRIDAY, Feb. 6 (HealthDay News) -- Hormones and a cell receptor in the kidneys may explain why premenopausal women have fewer problems than men with salt-sensitive hypertension, a new study says.

Salt-sensitive hypertension occurs when the kidneys hold onto more sodium than necessary. This drives up blood pressure as the body tries to force the kidneys to get rid of excess salt. Endothelin B (ETB) receptors, found in the blood vessels and tubules of the kidney, are thought to act as gatekeepers, deciding how much salt the body should excrete.

"We know from other studies we have done that this endothelin B receptor is critical to keeping you from becoming hypertensive when you eat salt," investigator Dr. David Pollock, a renal physiologist in the Vascular Biology Center at the Medical College of Georgia, said in a news release issued by the university.

However, endothelin A (ETA) receptors counteract their siblings' work by signaling when to increase blood pressure. ETA antagonist drugs, which block the receptors, are already used to control pulmonary hypertension.

Tests on rats showed ETA receptors do not reduce blood flow to the kidneys in female rats as much as they do to male rats. Instead, they actually increase sodium output without increasing blood pressure.

When researchers removed the ovaries of the female rats, they responded more like the males. Estrogen, Pollack said, appeared to improve the action of the ETA receptors.

The findings were published in the February issue of Hypertension.

The researchers plan more studies into different receptor subtypes. Meanwhile, colleagues at the University of Edinburgh in Scotland have begun studying how ETA receptor blockers may impact sodium excretion.

More information

The American Heart Association has more about

Copyright©2009 ScoutNews,LLC.
All rights reserved  

1

GOOD

Page: 1 2

Related medicine news :

1. The Female Health Company Schedules First Quarter Conference Call for February 10, 2009
2. Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher
3. FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable
4. Surprising Results on Smoking Research Hispanic Versus White Female Smokers
5. Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom
6. The Female Health Company Schedules Year End FY2008 Conference Call for December 1, 2008
7. Surprisingly, female models have negative effect on men
8. Large-Scale Survey Reveals Low Sexual Desire Most Common Distressing Female Sexual Problem, Affecting Up to One in 10 Women
9. Sexual Trauma Haunts Many Female Vets
10. The Health Insurance Advocate Radio Show Expands to Springfield, Missouri, and Reaches a New All-Time Ratings High for Female Listenership
11. Reese Witherspoon Visits Brazil to Spread Message of Female Empowerment as Avons Global Ambassador
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Female Hormones Deter Salt-Sensitive Hypertension
Female Hormones Deter Salt-Sensitive Hypertension
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 1SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 4Studying cancer in pet dogs to find new treatments for human patients 59325 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8